FX06 Platform
Septic/Hemorrhagic Shock, Severe Viral Infections (e.g., Ebola, Dengue)
Pre-clinical/ResearchActive
Key Facts
Indication
Septic/Hemorrhagic Shock, Severe Viral Infections (e.g., Ebola, Dengue)
Phase
Pre-clinical/Research
Status
Active
Company
About F4 Pharma
F4 Pharma is an Austrian preclinical/clinical-stage biotech targeting serious conditions driven by endothelial dysfunction and capillary leak, such as ARDS and Clarkson disease. Its core technology is a novel anti-inflammatory peptide platform, with its most advanced candidate, FX06, entering clinical trials for ARDS. The company operates as a private, pre-revenue entity aiming to address significant unmet medical needs in critical care and orphan diseases.
View full company profile